Solid Biosciences Inc (SLDB) News

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”...

Form EFFECT - Notice of Effectiveness

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

— Presentations to highlight AAV manufacturing and purification improvements, vector biology updates,and a...

Form 4 - Statement of changes in beneficial ownership of securities

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences...

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations...

Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium

CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences...

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds...